Activated protein C resistance in patients with central retinal vein occlusion

British Journal of Ophthalmology

Volumn 81, Issue 10, 1997, Pages 832-834

  Larsson, J ^a   Sellman, A ^b   Bauer, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b Medical Center Hospital of Helsingborg   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030728427     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.81.10.832     Document Type: Article

References (33)

1. McGrath MA, Wechsler F, Hunyor ABL, Penny R. Systemic factors contributory to retinal vein oclusion. Arch Intern Med 1978;138:216-20.
2. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation: see comments. Thromb Haemost 1992;68:7-13.
3. Taberno MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991;36:249-54.
4. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
5. Dahlbäck B, Svensson PJ. Nyupptäckt rubbning i antikoagulationen resistens mot protein C orsak till trombos. Lakartidningen 1994;91:50-3.
6. Dahlbäck B. Inherited resistance to activated protein C, a major cause of venous thrombosis, is due to a mutation in the factor V gene. Haemostasis 1994;24:139-51.
7. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V asociated with resistance to activated protein C. Nature 1994;369:64-7.
8. Greengard JS, Xiao Xiu XS, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994;343:1361-2.
9. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994;330: 517-22.
10. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
11. van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V (letter). Nature Med 1995;1:185.
12. Hellgren M, Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol 1995;173:210-3.
13. Chan LC, Bourke C, Lam CK, Liu AW, Brookes S, Jenkins V, et al. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors - correlation with absence of Arg506-Gln mutation of factor V gene (letter). Thromb Haemost 1996;75:522-3.
14. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
15. Holm J, Zoller B, Berntorp E, Erhardt L, Dahlbäck B. Prevalence of factor V gene mutation among myocardial infarction patients and healthy controls is higher in Sweden than in other countries. J Intern Med 1996;239:221-6.
16. Majerus PW. Human genetics. Bad blood by mutation (news; comment). Nature 1994;369:14-5.
17. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995;85: 1504-8.
18. Dahlback B, Hillarp A, Rosen S, Zoller B. Resistance to activated protein C, the FV:Q506 allele, and venous thrombosis. Ann Hematol 1996;72:166-76.
19. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993;342:1503-6.
20. Legnani C, Palareti G, Biagi R, Coccheri S. Activated protein C resistance in deep vein thrombosis. Lancet 1994; 343:541-2.
21. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion (see comments). Br J Ophthalmol 1996;80:200-2.
22. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C:prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
23. Denson KW, Reed SV, Haddon ME. The modified APC resistance test (letter). Thromb Haemost 1995;74:995.
24. Trossaert M, Conard J, Horellou MH, Elalamy I, Samama MM. The modified APC resistance test in the presence of factor V deficient plasma can be used in patients without oral anticoagulant (letter). Thromb Haemost 1996;75:521-2.
25. Jorquera JI, Montoro JM, Fernandez MA, Aznar JA, Aznar J. Modified test for activated protein C resistance (letter) (see comments). Lancet 1994;344:1162-3.
26. Zöller B, Svensson PJ, He, X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
27. Williamson TH, Rumley A, Lowe GD. Blood viscosity, coagulation, and activated protein C resistance in central retinal vein occlusion: a population controlled study (see comments). Br J Ophthalmol 1996;80:203-8.
28. Alhenc Gelos M, Gandrille S, Aubry ML, Emmerich J, Flessinger JN, Aiach M. Unexplained thrombosis and factor V Leiden mutation (letter) (see comments). Lancet 1994;344:555-6.
29. Baker R, Thom J, van Bockxmeer F. Diagnosis of activated protein C resistance (factor V Leiden) (letter; comment). Lancet 1994;344:1162.
30. Voorberg J, Roelse J, Koopman R, Buller H, Berends F, ten Cate JW, et al. Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V (see comments). Lancet 1994;343:1535-6.
31. Freyburger G, Bilhou-Nabera C, Dief S, Javorschi S, Labrouche S, Lerebeller MJ, et al. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost 1996;75:460-5.
32. Zöller B, Dahlbäck B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis (see comments). Lancet 1994;343: 1536-8.
33. Linna T, Ylikorkala A, Kontula K, Puska P, Tervo T. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997;77:212-6.